ApoB (apolipoprotein B) is a protein that sits on the surface of cholesterol-carrying particles in your blood. Every LDL particle, often called “bad cholesterol,” has exactly one ApoB molecule on it, which makes ApoB a direct count of how many of these harmful particles are circulating in your bloodstream. Many cardiologists now consider it a more accurate predictor of heart disease risk than the standard LDL cholesterol number on a typical lipid panel.
What ApoB Actually Does
Cholesterol doesn’t dissolve in blood. To get from one part of your body to another, it has to be packaged into tiny spheres called lipoproteins, with fats tucked inside and proteins wrapped around the outside. ApoB is the main protein on the surface of these packages. It acts as both structural scaffolding and an address label, telling your cells when to pull the particle out of circulation.
Your body makes two forms. ApoB-100 is produced by the liver and appears on LDL, VLDL, and other particles that carry cholesterol through the bloodstream. ApoB-48 is made in the small intestine and sits on chylomicrons, the particles that absorb dietary fat after you eat. Both forms come from the same gene, but an editing process in the intestine cuts the protein roughly in half to create the shorter version. When people talk about ApoB in the context of heart disease, they’re almost always referring to ApoB-100.
One detail makes ApoB uniquely useful: there is exactly one ApoB molecule per particle. That means measuring ApoB in a blood sample gives you the total number of potentially harmful particles, not just the amount of cholesterol riding inside them. Two people can have the same LDL cholesterol level but very different particle counts, and the person with more particles faces higher risk.
Why ApoB Predicts Heart Disease Better Than LDL
Standard cholesterol tests measure how much cholesterol is packed inside LDL particles, reported as LDL-C. But LDL particles vary in size. Some are large and carry a lot of cholesterol each; others are small and carry less. If your particles tend to be small, your LDL-C number can look normal even though you have a large number of particles doing damage. This mismatch, called discordance, is especially common in people with metabolic syndrome, type 2 diabetes, or high triglycerides.
A large review of studies found that ApoB outperformed LDL-C in 9 out of 9 head-to-head comparisons for predicting cardiovascular events. It also beat non-HDL cholesterol, another commonly used estimate, in 7 out of 9 comparisons. The researchers concluded that neither LDL-C nor non-HDL-C are adequate stand-ins for ApoB, and that ApoB should be the primary measure used to estimate cardiovascular risk from these particles.
How ApoB Particles Cause Plaque
The trapping of ApoB-containing particles inside artery walls is what starts and sustains the entire process of atherosclerosis, from the earliest fatty streaks to the advanced plaques that can rupture and cause heart attacks or strokes. Here’s the basic sequence: ApoB particles in your blood pass through the thin inner lining of an artery. Most pass through harmlessly. But some get stuck, binding to sugar-protein structures in the artery wall called glycosaminoglycans. Once trapped, these particles trigger an inflammatory response that gradually builds into plaque.
The higher the concentration of ApoB particles in your blood, the more particles enter the artery wall and the more get trapped. Particle size matters too. Smaller, cholesterol-depleted ApoB particles slip into the artery wall more easily and bind more tightly once inside, making them more likely to get stuck than larger particles. This is another reason ApoB testing adds information beyond a standard cholesterol number: it captures the full picture of atherogenic particle burden regardless of particle size.
What Your ApoB Number Means
ApoB is measured in milligrams per deciliter (mg/dL). Guidelines from major cardiology organizations set different targets depending on your overall risk profile:
- Low to moderate risk: Below 100 mg/dL is the European Society of Cardiology’s target for moderate-risk individuals. The National Lipid Association recommends below 90 mg/dL for primary prevention.
- High risk: Below 80 mg/dL is the target set by European guidelines and the National Lipid Association for people at high risk, such as those with diabetes plus additional risk factors.
- Very high risk: Below 65 mg/dL is the European target for people at very high risk, such as those with established cardiovascular disease. Some experts suggest matching ApoB targets directly to LDL-C targets, meaning below 55 mg/dL for the highest-risk patients.
- Elevated risk flag: The American Heart Association and American College of Cardiology consider an ApoB level above 130 mg/dL a risk-enhancing factor that should influence treatment decisions.
A practical shortcut proposed in a recent review in Circulation: because on-treatment LDL-C levels and ApoB levels tend to be nearly identical numerically, the same number can serve as the target for both. If your LDL-C goal is below 70, your ApoB goal is also below 70.
Getting an ApoB Test
ApoB is measured with a simple blood draw, and unlike a standard lipid panel, you don’t need to fast beforehand. If your provider is ordering both an ApoB test and a lipid panel at the same time, you should avoid eating or drinking anything except water for 12 hours before the draw, since the lipid panel requires fasting.
ApoB testing is especially valuable if you have conditions that make standard LDL-C unreliable. People with metabolic syndrome, type 2 diabetes, or high triglycerides often have smaller, denser LDL particles. In these cases, LDL-C can underestimate the actual number of harmful particles, while ApoB gives a more accurate count. If your triglycerides are consistently above 150 mg/dL or your LDL-C and ApoB seem mismatched, ApoB becomes the more trustworthy number for gauging your risk.
How To Lower ApoB
The same interventions that lower LDL cholesterol also reduce ApoB, since you’re shrinking the pool of particles that carry ApoB on their surface. Statins are the most widely prescribed and potent ApoB-lowering treatment. For most people, a statin at moderate to high intensity will bring ApoB down significantly. For those who don’t reach their target with statins alone, particularly people with genetic conditions like familial hypercholesterolemia, newer medications that block a protein called PCSK9 can produce dramatic additional reductions.
Lifestyle changes move ApoB in the right direction too. Reducing saturated fat intake, replacing refined carbohydrates with fiber-rich whole foods, losing excess weight, and exercising regularly all contribute to lower particle counts. These changes tend to have a more modest effect than medication, but they improve cardiovascular risk through multiple pathways beyond just ApoB, including blood pressure, blood sugar, and inflammation. For people with mildly elevated ApoB and no other major risk factors, lifestyle changes may be enough. For those at higher risk, they’re an important addition to medication rather than a substitute.